Assortment analysis of beta-blockers on the pharmaceutical market of the Republic of Uzbekistan
https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.332
Abstract
Background. Beta-adrenergic blockers, or beta-blockers (BBs), are a crucial class of medications. Given their extensive use in the management of cardiovascular diseases, regular analysis of BB availability and range in the pharmaceutical market is essential.
Objective: To analyze the range of BBs available on the pharmaceutical market of the Republic of Uzbekistan, taking their quantitative composition, countries of origin, and dosage forms into account.
Material and methods. The study utilized data from the State Register of medicines, medical devices and medical equipment approved for use in medical practice in the Republic of Uzbekistan. Methods employed included systematization, statistical and comparative analysis, and graphical representation of the results.
Results. The Uzbek pharmaceutical market is dominated by metoprolol, bisoprolol, and nebivolol, with the majority of products manufactured in the countries of the near and far abroad such as India, Russia, and Germany. Solid dosage forms, specifically tablets and capsules, are prevalent in this sector, which is consistent with the therapeutic use of this drug class.
Conclusion. The range of BBs in the pharmaceutical market of Uzbekistan is extensive in terms of international nonproprietary names, trade names, and manufacturing origins. This reflects consistent demand and the clinical importance of this drug group in the management of cardiovascular conditions. The findings can be used to further improve the pharmaceutical supply system.
About the Authors
N. M. U. Sultanbaeva
Institute of Pharmaceutical Education and Research
Uzbekistan
Uzbekistan
Nargiza М. Sultanbayeva, PhD
46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114
Sh. Z. Umarova
Institute of Pharmaceutical Education and Research
Uzbekistan
Uzbekistan
Shakhnoz Z. Umarova, PhD, Prof.
46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114
References
1. Khuzhanov H., Kobilov O., Niyozova Sh. Arterial hypertension: clinical aspects, diagnostics and modern approaches to treatment. Multidisciplinary Journal of Science and Technology. 2024; 4 (10): 102–9 (in Russ.).
2. Soboleva G.N., Rogoza A.N., Shumilina M.V., et al. Endothelial dysfunction in arterial hypertension: vasoprotective effects of new generation beta-blockers. Russian Medical Journal. 2001; 9 (18): 754–7 (in Russ.).
3. Arutyunov G.P., Oganezova L.G. Beta-blockers and renal continuum. Clinical Nephrology. 2009; 2: 43–51 (in Russ.).
4. Stepanova A.A., Lebedev O.V. Historical excursion into beta-blockers. In: Zakharova A.N. (Ed.) Collection of scientific papers of young scientists and specialists. Cheboksary: Ulyanov Chuvash State University; 2022: 483–6 (in Russ.).
5. Koracevic G., Micic S., Stojanovic M., et al. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class. Curr Vasc Pharmacol. 2021; 19 (4): 343–6. https://doi.org/10.2174/1570161118666200518113833.
6. Ziff O.J., Samra M., Howard J.P., et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and metaanalytic assessment. BMC Med. 2020; 18 (1): 103. https://doi.org/10.1186/s12916-020-01564-3.
7. Umarova Sh.Z., Sultanbaeva N.M.U., Sharipova M.B.K. Analysis of registration in the State Register of the Republic of Uzbekistan of drugs used for cardiovascular system diseases. Young Scientist. 2020; 8: 82–9 (in Russ.).
8. Oken M.K., Zhakipbekov K.S., Dyusembinova G.A. Marketing analysis of medicines of the beta-adrenoblocker group in the treatment of cardiovascular diseases. Farmatsiya Kazakhstana / Pharmacy of Kazakhstan. 2020; 5: 7–11 (in Russ.).
9. Gromova I.P. Marketing analysis of beta-adrenergic blocking agents used in the treatment of hypertension. In: Youth of the Great Volga: a collection of articles by laureates of the 21st Interregional ConferenceFestival of Scientific Creativity of Student Youth. Cheboksary: Center for Youth Initiatives; 2019: 332–34 (in Russ.).
10. Varyukhina N.V. Marketing research of selective beta-blockers in a pharmacy organization. In: Current issues in modern medicine: proceedings of the 2nd Far Eastern Medical Youth Forum. Khabarovsk: Far Eastern State Medical University; 2018: 232–3 (in Russ.).
What is already known about thе subject?
► Beta-blockers (BBs) hold key positions in clinical guidelines for managing cardiovascular diseases, including hypertension and heart failure
► The availability and prevalence of BBs vary across different pharmaceutical markets
What are the new findings?
► The study identified 16 international nonproprietary names of BBs registered in Uzbekistan, which were represented by 53 trade names as of 2025
► India, Uzbekistan, and Germany account for the largest share of the registed BBs in the Uzbek market
► The increasing share of locally produced drugs reflect the import substitution policy
How might it impact the clinical practice in the foreseeable future?
► The findings can help optimize the pharmacy assortment of BBs thus improving patient access to treatments
► Gaps in the current range suggest potential for expanding the use of modern selective BBs
► Increasing the share of domestic drugs may improve access to treatments for patients
Review
For citations:
Sultanbaeva N.M., Umarova Sh.Z. Assortment analysis of beta-blockers on the pharmaceutical market of the Republic of Uzbekistan. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2026;1(19):69-78. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.332
Views:
385
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 